Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. Triplete reset trial

International Journal of Cardiology

Volumn 194, Issue , 2015, Pages 60-62

  Sardella, Gennaro ^a,c   Calcagno, Simone ^a   Mancone, Massimo ^a   Lucisano, Luigi ^a   Pennacchi, Mauro ^a   Stio, Rocco Edoardo ^a   Placentino, Filippo ^a   Di Roma, Angelo ^a   Cavallo, Erika ^a   Palmirotta, Raffaele ^b   Guadagni, Fiorella ^b   Fedele, Francesco ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Clopidogrel; Genetics; High on treatment platelet reactivity; Prasugrel; Stable coronary artery disease; Ticagrelor

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; BLEEDING; CONTROLLED STUDY; DRUG MEGADOSE; FOLLOW UP; GENETIC VARIABILITY; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; LETTER; MAJOR CLINICAL STUDY; PARALLEL DESIGN; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GENOTYPE; PHYSIOLOGY; PROCEDURES; THROMBOCYTE;

ADENOSINE; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP2C19; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VARIATION; GENOTYPE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84930948000     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.05.085     Document Type: Article

References (10)

1. M.J. Price, P.B. Berger, P.S. Teirstein, and GRAVITAS Investigators Standard- vs high-dose Clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
2. J.P. Collet, T. Cuisset, G. Rangé, and ARCTIC Investigators Bedside monitoring to adjust antiplatelet therapy for coronary stenting N. Engl. J. Med. 367 2012 2100 2109
3. G. Sardella, S. Calcagno, and M. Mancone Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE trial Circ. Cardiovasc. Interv. 5 2012 698 704
4. J.S. Hulot, J.P. Collet, and J. Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19∗2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J. Am. Coll. Cardiol. 56 2010 134 143
5. S.D. Wiviott, E. Braunwald, C.H. McCabe, and TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 357 2007 2001 2201
6. L. Wallentin, R.C. Becker, A. Budaj, PLATO Investigators, A. Freij, and M. Thorsén Ticagrelor versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 361 2009 1045 1057
7. R. Mehran, S.V. Rao, D.L. Bhatt, and H. White Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
8. D. Alexopoulos, G. Dimitropoulos, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel the importance of CYP2C19∗2 genotyping JACC Cardiovasc. Interv. 4 2011 403 410
9. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J. Am. Coll. Cardiol. 53 10 Mar 10 2009 849 856
10. J.L. Mega, S.L. Close, and S.D. Wiviott Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 9749 Oct 16 2010 1312 1319